Investment
Samsung Invests in Generate: Biomedicines to Advance AI-Driven Protein Therapeutics Discovery
Samsung Biologics
PR-12-24-NI-141Dec 18, 2024
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
Pharma's Almanac
PAO-06-022--RT-01Jun 24, 2022
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Pharma's Almanac
O-06-022--RT-01Jun 24, 2022
M&A
Samsung Biologics Reaches Agreement With Biogen to Acquire Full Ownership of Samsung Bioepis
Samsung Biologics
PR-M01-22-21Jan 28, 2022
Biosimilar
FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)
Samsung Bioepis
PA2329Jul 26, 2019
Phase I
Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein
Samsung Bioepis
PR-M09-18-NI-007Sep 05, 2018
Partnership
Samsung to Develop Novel Drugs
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M09-17-NI-002Sep 01, 2017
Partnership
Collaboration Seeks Novel Pancreatitis Therapies
Nice Insight
PAO-M08-17-NI-037Aug 29, 2017